The vast majority of patients with non-valvular atrial fibrillation (AF) are managed with the administration of anticoagulation (blood-thinners) to reduce their risk of clot formation and stroke risk.
In some patients, these medications are associated with a risk of significant and potentially life-threatening bleeding. In these instances where this strategy is contraindicated, LAAO may be suitable to reduce the risk of future stroke.